Chadi invites Amy Barhorst, MD, and Rocco Pallin, colleagues at UC Davis Health, to tackle the stigma and underdiagnosing of mental health in America and how mental illness intersects with gun violence in this country. The experts delve into whether community and person-to-person violence should be largely attributed to mental illness as well as why policy changes are the clearest way to eliminate mass shootings. Then, the conversation pivots to a true story of how their Review article on ways HCPs can help prevent injury and suicide from firearms was rejected and then plagiarized by the journal editor, all of which was all covered in a viral Twitter thread.
View Dr. Barnhorst’s interview with CNN on whether shootings are a mental health issue: https://www.cnn.com/videos/tv/2018/11/27/exp-gps-1125-gupta-barnhorst-mental-health-guns.cnn
Read Dr. Barnhorst’s op-ed in the New York Times on why the mental health system cannot stop mass shooters: https://www.nytimes.com/2018/02/20/opinion/mental-health-stopping-mass-shooters.html
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
